empagliflozin/linagliptin vs ranolazine
Side-by-side comparison of empagliflozin/linagliptin and ranolazine. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
moderate Known Drug Interaction
Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3) ] .
Recommendation: Talk to your doctor about monitoring your blood sugar and checking for signs of too much metformin in your system.
Glyxambi
Ranexa
Glyxambi is a drug that combines three medicines to help lower blood sugar in adults with type 2 diabetes. It can also lower the risk of death from heart problems in those with both type 2 diabetes and heart disease.
Ranolazine extended-release tablets help treat chronic angina (chest pain). It can be used with other heart medicines.
Glyxambi is used to improve blood sugar control in adults with type 2 diabetes. It should be used along with diet and exercise. Glyxambi can also help lower the risk of death caused by heart problems if you have both type 2 diabetes and heart disease. It is not for people with type 1 diabetes.
Ranolazine is used to treat chronic angina, which is chest pain that keeps coming back. It can help you have fewer angina episodes. You can take this medicine with other drugs like beta-blockers or nitrates.
Glyxambi works in three ways to lower blood sugar. Empagliflozin helps your kidneys remove sugar from your blood through urine. Linagliptin helps your body release more insulin after meals. Metformin helps to decrease the amount of sugar your liver makes and helps your body use insulin better.
Ranolazine works by affecting the sodium channels in your heart cells. This helps to improve blood flow to your heart. It reduces the amount of calcium in your heart, which can help prevent angina.
- • Upper respiratory infection (like a cold)
- • Urinary tract infection
- • Runny or stuffy nose
- • Diarrhea
- • Constipation
- • Dizziness
- • Headache
- • Constipation
- • Nausea
- Increased blood sugar 146
- Diabetic ketoacidosis 144
- Feeling sick to your stomach 102
- Fungal infection 92
- Weight loss 86
- Death 816
- Heart attack 640
- Chest pain 605
- Angina 594
- Stent placement 582
Glyxambi contains metformin, which can cause a serious side effect called lactic acidosis. Lactic acidosis is a buildup of lactic acid in the blood. It can be life-threatening. Get medical help right away if you have symptoms like feeling very weak, tired, or uncomfortable; unusual muscle pain; trouble breathing; stomach pain with nausea and vomiting; feeling cold, especially in your arms and legs; feeling dizzy or lightheaded; or a sudden change in your heartbeat.
Ranolazine can cause changes in your heart's electrical activity (QT prolongation). If you have kidney problems, your doctor should check your kidney function. If you develop kidney failure, stop taking ranolazine.
Glyxambi is not recommended during the second and third trimesters of pregnancy due to potential harm to the baby's kidneys. It is also not recommended while breastfeeding. Talk to your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
It is not known if ranolazine can harm an unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if ranolazine passes into breast milk. Discuss with your doctor if you are breastfeeding.
How to Read This empagliflozin/linagliptin vs ranolazine Comparison
empagliflozin/linagliptin is classified in the SGLT2 / DPP-4 Combination drug class, while ranolazine sits within the Late Sodium Current Inhibitor (Antianginal) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, empagliflozin/linagliptin has 570 submissions while ranolazine has 3,237. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known moderate interaction flagged in FDA labeling, attributed to ranolazine prevents the kidneys from properly removing metformin from your system, leading to higher amounts of the drug in your body. this can increase the chance of developing a dangerous buildup of acid in your blood.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between empagliflozin/linagliptin and ranolazine - always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.